Results of shareholder votes disclosed under 8-K Item 5.07.
BOSTON SCIENTIFIC CORP shareholders rejected Stockholder proposal to give shareholders ability to call special meeting at the 2026-04-30 meeting.
“(8) The stockholders did not approve the stockholder proposal titled “Give Shareholders the Ability to Call for a Special Shareholder Meeting.” For Against Abstain Broker Non-Votes 516,140,863 689,739,605 4,513,925 81,271,529”
BOSTON SCIENTIFIC CORP shareholders rejected Amendment to permit stockholders owning 25% to call special meeting at the 2026-04-30 meeting.
“(7) The stockholders did not approve the amendment of the Company’s Third Restated Certificate of Incorporation and Amended and Restated By-Laws to permit stockholders owning not less than 25% of the Company’s common stock to call a special meeting of stockholders. For Against Abstain Broker Non-Votes 1,095,371,430 20,945,183 94,077,780 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of certificate of incorporation to provide for exculpation of officers at the 2026-04-30 meeting.
“(6) The stockholders approved the amendment of the Company’s Third Restated Certificate of Incorporation to provide for exculpation of certain officers as permitted by Delaware law. For Against Abstain Broker Non-Votes 1,057,086,923 150,458,633 2,848,837 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of certificate of incorporation to remove supermajority voting provisions at the 2026-04-30 meeting.
“(5) The stockholders approved the amendment of the Company’s Third Restated Certificate of Incorporation to remove supermajority voting provisions. For Against Abstain Broker Non-Votes 1,189,271,431 17,774,053 3,348,909 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Amendment of Employee Stock Purchase Plan to increase shares reserved at the 2026-04-30 meeting.
“(4) The stockholders approved the amendment of the Company’s Employee Stock Purchase Plan to increase the number of shares reserved for issuance. For Against Abstain Broker Non-Votes 1,205,130,032 2,818,667 2,445,694 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-04-30 meeting.
“(3) The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year. For Against Abstain Broker Non-Votes 1,169,955,769 116,874,243 4,835,910 0”
BOSTON SCIENTIFIC CORP shareholders approved Advisory vote on executive compensation at the 2026-04-30 meeting.
“(2) The stockholders approved, on an advisory basis, the compensation of the Company’s “Named Executive Officers” as disclosed in the Company’s proxy statement for the Annual Meeting. For Against Abstain Broker Non-Votes 1,096,889,576 110,645,813 2,859,004 81,271,529”
BOSTON SCIENTIFIC CORP shareholders approved Election of 10 director nominees at the 2026-04-30 meeting.
“(1) All 10 director nominees were elected to the Board for a one-year term, to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their successors have been elected and qualified. Nominee For Against Abstain Broker Non-Votes David C. Habiger 1,037,805,652 169,730,106 2,858,635 81,271,529 Edward J. Ludwig 1,156,469,560 50,835,636 3,089,197 81,271,529 Michael F. Mahoney 1,113,612,016 93,613,027 3,169,350 81,271,529 Jessica L. Mega 1,196,020,676 11,532,045 2,841,672 81,271,529 Susan E. Morano 1,171,890,417 35,662,932 1,841,044 81,271,529 Cheryl Pegus 1,195,889,562 11,653,832 2,850,999 81,271,529 Cathy R. Smith 1,117,908,896 88,044,911 4,440,586 81,271,529 Christophe P. Weber 1,205,365,637 2,260,256 2,768,500 81,271,529 David S. Wichmann 1,198,736,185 8,393,038 3,265,170 81,271,529 Ellen M. Zane 1,150,092,668 56,753,553 3,548,172 81,271,529”
NORWOOD FINANCIAL CORP shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2026-04-28 meeting.
“3. The approval of a non-binding advisory resolution regarding the compensation of the Company’s named executive officers. For Against Abstain Broker Non-Votes 5,282,802 802,735 237,295 1,986,804”
NORWOOD FINANCIAL CORP shareholders approved Ratification of appointment of S.R. Snodgrass, P.C. as independent registered public accounting firm for 2026 at the 2026-04-28 meeting.
“2. The ratification of the appointment of S.R. Snodgrass, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026. For Against Abstain Broker Non-Votes 7,956,697 51,063 301,876 —”
NORWOOD FINANCIAL CORP shareholders approved Election of directors for three-year terms at the 2026-04-28 meeting.
“1. The following individuals were elected to serve as a director of the Company each for a three-year term or until his successor is duly elected and qualified, by the following vote: For Withhold Broker Non-Votes Kevin M. Lamont 5,723,340 599,492 1,986,804 Dr. Kenneth A. Phillips 5,740,131 582,701 1,986,804 Jeffrey S. Gifford 6,201,415 121,417 1,986,804”
RTX Corp shareholders approved A proposal to appoint PricewaterhouseCoopers LLP, a firm of independent registered public accountants, to serve as the Company’s Independent Auditor for 2026 until the next Annual Meeting in 2027 at the 2026-04-30 meeting.
“A proposal to appoint PricewaterhouseCoopers LLP, a firm of independent registered public accountants, to serve as the Company’s Independent Auditor for 2026 until the next Annual Meeting in 2027. The proposal was approved, and the voting results are as follows: Votes For Votes Against Abstentions 1,136,798,685 56,260,230 1,430,916”
RTX Corp shareholders approved A proposal that shareowners approve, on an advisory basis, the compensation of the Company’s named executive officers at the 2026-04-30 meeting.
“A proposal that shareowners approve, on an advisory basis, the compensation of the Company’s named executive officers. The proposal was approved, and the voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 1,006,669,958 35,108,448 4,157,853 148,553,572”
RTX Corp shareholders approved Election of Directors at the 2026-04-30 meeting.
“The following individuals were elected to serve as directors for a term expiring at the 2027 Annual Meeting of Shareowners or upon the election and qualification of their successors. The voting results for each of the nominees are as follows: Nominee Votes For Votes Against Abstentions Broker Non-Votes Tracy A. Atkinson 1,024,829,855 19,226,248 1,880,156 148,553,572 Christopher T. Calio 1,016,311,707 27,803,159 1,821,393 148,553,572 Leanne G. Caret 1,030,281,922 13,729,836 1,924,501 148,553,572 Bernard A. Harris, Jr. 1,031,640,417 12,309,610 1,986,232 148,553,572 George R. Oliver 1,009,990,771 33,352,993 2,592,495 148,553,572 Ellen M. Pawlikowski 1,032,314,692 11,763,835 1,857,732 148,553,572 Denise L. Ramos 1,020,920,779 22,468,559 2,546,921 148,553,572 Fredric G. Reynolds 1,019,834,007 24,120,266 1,981,986 148,553,572 Brian C. Rogers 1,030,612,420 13,355,210 1,968,629 148,553,572 Robert O. Work 975,945,794 67,932,773 2,057,692 148,553,572”
INTUITIVE SURGICAL INC shareholders approved Approval of amendment and restatement of Amended and Restated 2010 Incentive Award Plan.
“Proposal No. 4 : To approve the amendment and restatement of the Company’s Amended and Restated 2010 Incentive Award Plan: For Against Abstain Broker Non-votes 260,005,547 22,129,032 1,056,767 29,960,297”
INTUITIVE SURGICAL INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditor at the 2026-12-31 meeting.
“Proposal No. 3 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstain 308,789,950 4,067,630 294,063”
INTUITIVE SURGICAL INC shareholders approved Advisory vote on compensation of Named Executive Officers.
“Proposal No. 2 : To consider and approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement: For Against Abstain Broker Non-votes 265,030,878 17,018,702 1,141,766 29,960,297”
INTUITIVE SURGICAL INC shareholders approved Election of ten members to the Board.
“Proposal No. 1 : To elect ten members to the Board to serve until the 2027 Annual Meeting of Stockholders: Nominee For Against Abstain Broker Non-votes Craig H. Barratt, Ph.D. 273,151,253 9,610,497 429,596 29,960,297”
Dauch Corp shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026 at the 2026-04-30 meeting.
“The proposal to ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the votes shown below.”
Dauch Corp shareholders approved Approval of Amended and Restated 2018 Omnibus Incentive Plan at the 2026-04-30 meeting.
“Dauch's stockholders voted to approve the Plan by the vote shown below.”
Dauch Corp shareholders approved Advisory vote on named executive officer compensation at the 2026-04-30 meeting.
“Dauch's stockholders voted for, on a non-binding, advisory basis, the compensation of Dauch's officers, by the vote shown below.”
Dauch Corp shareholders approved Election of three directors to serve for three-year terms expiring in 2029. at the 2026-04-30 meeting.
“At the meeting, Dauch's stockholders voted on four proposals and cast their votes as shown below.”
TREX CO INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-04-28 meeting.
“Trex stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2026. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 85,831,316 3,694,637 77,793 —”
TREX CO INC shareholders approved Advisory approval of the compensation of the Company's executive officers at the 2026-04-28 meeting.
“Trex stockholders approved, on an advisory basis, the compensation of the Company’s executive officers named in the Company’s definitive proxy statement dated March 16, 2026. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 44,939,698 34,703,577 1,994,660 7,965,811”
TREX CO INC shareholders approved Election of four directors to serve for a three-year term until the 2029 annual meeting at the 2026-04-28 meeting.
“Trex stockholders elected four directors to the Board to serve for a three-year term until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes Jay M. Gratz 77,422,353 4,146,966 68,616 7,965,811 B. Andrew Rose 80,093,491 1,472,318 72,126 7,965,811 Irene Tasi 80,111,535 1,460,409 65,991 7,965,811 Gerald Volas 74,080,206 7,488,206 69,523 7,965,811”
WILLIAMS COMPANIES, INC. shareholders approved Ratify the Selection of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2026 at the 2026-12-31 meeting.
“Ernst and Young LLP was ratified as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”
WILLIAMS COMPANIES, INC. shareholders approved Approve the Amendment and Restatement of The Williams Companies, Inc. 2007 Employee Stock Purchase Plan to Increase the Number of Issuable Shares from 5,200,000 to 7,200,000, Extend the Term Six Years, and Make Other Amendments.
“Stockholders approved the Amendment and Restatement of The Williams Companies, Inc. 2007 Employee Stock Purchase Plan to increase the number of issuable shares from 5,200,000 to 7,200,000, extend the term six years, and make other amendments.”
WILLIAMS COMPANIES, INC. shareholders approved Approve the Amendment and Restatement of The Williams Companies, Inc. 2007 Incentive Plan to Increase the Number of Issuable Shares from 50,000,000 to 85,000,000, Remove the Plan Expiration Date, Increase the Annual Director Equity Grant Limit, Eliminate Share Recycling for Tax Withholding, Remove C.
“Stockholders approved the Amendment and Restatement of The Williams Companies, Inc. 2007 Incentive Plan to increase the number of issuable shares from 50,000,000 to 85,000,000, remove the plan expiration date, increase the annual director equity grant limit, eliminate share recycling for tax withholding, remove certain change in control provisions, and make other amendments.”
WILLIAMS COMPANIES, INC. shareholders approved Approve, on an Advisory Basis, the Compensation of our Named Executive Officers.
“Stockholders approved, on an advisory basis, the compensation of our named executive officers.”
WILLIAMS COMPANIES, INC. shareholders approved Election of Ten Director Nominees for a One-year Term.
“Each of the director nominees was elected to the Company’s Board of Directors to serve a one-year term expiring at the Company’s next annual meeting of stockholders.”
Innoviva, Inc. shareholders approved Approval of 2026 Equity Incentive Plan at the 2026-05-04 meeting.
“At the Meeting, our stockholders also approved Innoviva’s 2026 Equity Incentive Plan. The vote for such approval was 55,435,111 shares for, 3,766,788 shares against, 36,028 shares abstaining, and 6,809,010 shares of broker non-votes.”
Innoviva, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2026-05-04 meeting.
“Also at the Meeting, our stockholders next ratified the selection by the Audit Committee of the Board of Directors of Innoviva of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 66,008,453 shares for, 16,574 shares against, 21,910 shares abstaining and 0 broker non-votes.”
Innoviva, Inc. shareholders approved Non-binding advisory vote on executive compensation at the 2026-05-04 meeting.
“At the Meeting, our stockholders next approved on a non-binding advisory basis, Innoviva’s executive compensation. The vote for such approval was 56,243,880 shares for, 2,836,001 shares against, 158,046 shares abstaining, and 6,809,010 shares of broker non-votes.”
Innoviva, Inc. shareholders approved Election of five directors at the 2026-05-04 meeting.
“At the Annual Meeting of Stockholders held on May 4, 2026 (the “Meeting”), the stockholders of Innoviva, Inc. (“Innoviva”) elected five members to our board of directors, each for a one-year term expiring at the annual meeting of stockholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Voted Against or Abstained Broker Non-Votes Derek Small 56,752,327 2,485,600 6,809,010 Mark A. DiPaolo, Esq. 50,072,119 9,165,808 6,809,010 Jules Haimovitz 56,834,625 2,403,302 6,809,010 Sarah J. Schlesinger, M.D. 53,509,479 5,728,448 6,809,010 Pavel Raifeld 58,880,013 357,914 6,809,010”
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ shareholders rejected Rejection of a shareholder proposal requesting a report on risks of misalignment between policies and customer base at the 2026-05-01 meeting.
“Rejection of a shareholder proposal requesting a report on risks of misalignment between policies and customer base. Votes For Votes Against Abstentions 2,437,588 106,027,693 890,086”
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ shareholders approved Approval, on a nonbinding advisory basis, of the compensation paid to the Bank's named executive officers with respect to the fiscal year ended December 31, 2025 at the 2026-05-01 meeting.
“Approval, on a nonbinding advisory basis, of the compensation paid to the Bank's named executive officers with respect to the fiscal year ended December 31, 2025. Votes For Votes Against Abstentions 103,158,563 5,616,200 580,604”
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ shareholders approved Ratification of the appointment of Ernst & Young LLP as the Bank's Independent Registered Public Accounting Firm to audit the Bank's financial statements for the fiscal year ending December 31, 2026 at the 2026-05-01 meeting.
“Ratification of the appointment of Ernst & Young LLP as the Bank's Independent Registered Public Accounting Firm to audit the Bank's financial statements for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions 120,123,130 5,420,488 301,120”
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ shareholders approved Election of 11 director nominees for a one-year term at the 2026-05-01 meeting.
“Election of 11 director nominees for a one-year term. Directors Votes For Votes Against Abstentions Maria Contereras-Sweet 107,949,568 952,459 453,340 Gary L. Crittenden 105,881,352 2,800,480 673,535 Suren K. Gupta 107,568,645 1,292,110 494,612 Claire A. Huang 107,888,433 1,005,377 461,557 Vivian S. Lee 105,894,891 2,732,190 728,286 Scott J. McLean 106,281,618 2,680,067 393,682 Edward F. Murphy 106,596,194 2,053,751 705,422 Stephen D. Quinn 104,315,607 4,353,098 686,662 Harris H. Simmons 105,426,222 3,605,443 323,702 Aaron B. Skonnard 107,486,121 1,373,674 495,572 Barbara A. Yastine 107,670,728 1,193,646 490,993”
Marker Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting if necessary to solicit additional votes on Proposal 3 at the 2026-05-01 meeting.
“Proposal No. 6 : Approval of the adjournment of the Annual Meeting in the event that the number of shares of Common Stock present or represented by proxy at the Annual Meeting and voting "FOR" the adoption of Proposal 3 is insufficient. The votes were cast as follows: Votes For Votes Against Abstained Adjournment 11,264,545 1,003,337 109,974 Broker Non-Votes: 0.”
Marker Therapeutics, Inc. shareholders approved Ratification of CBIZ as independent auditor for fiscal year 2026 at the 2026-05-01 meeting.
“Proposal No. 5 : Ratification of the selection by the Audit Committee of the Board of Directors of CBIZ CPAs P.C. ("CBIZ") as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The votes were cast as follows: Votes For Votes Against Abstained Ratification of appointment of CBIZ 11,626,068 1,003,337 109,974 Broker Non-Votes: 0.”
Marker Therapeutics, Inc. shareholders rejected Approval of Charter Amendment to revise voting threshold for increase or decrease of Common Stock at the 2026-05-01 meeting.
“Proposal No. 4: Approval of the adoption of an amendment to our Certificate of Incorporation, as amended, to revise the voting threshold required for an increase or decrease of Common Stock. The votes were cast as follows: Votes For Votes Against Abstained Approval of Charter Amendment to Revise Voting Threshold 8,279,190 1,222,558 71,209 Broker Non-Votes: 2,804,902.”
Marker Therapeutics, Inc. shareholders approved Approval of Charter Amendment to increase authorized shares from 30,000,000 to 130,000,000 at the 2026-05-01 meeting.
“Proposal No. 3: Approval of the adoption of an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of our Common Stock from 30,000,000 shares of Common Stock to 130,000,000 shares of Common Stock. The votes were cast as follows: Votes For Votes Against Abstained Approval of Charter Amendment to Increase Authorized Common Stock. 10,851,228 1,412,017 114,611 Broker Non-Votes: 0.”
Marker Therapeutics, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2026-05-01 meeting.
“Proposal No. 2 : Approval, on an advisory basis, of the compensation of the Company’s named executive officers. The votes were cast as follows: Votes For Votes Against Abstained Advisory approval of named executive officer compensation 8,548,905 471,261 552,789 Broker Non-Votes: 2,804,902.”
Marker Therapeutics, Inc. shareholders approved Election of five nominees to serve as directors at the 2026-05-01 meeting.
“Proposal No. 1 : Election of five nominees to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows: Name Votes For Votes Withheld David Eansor 9,297,478 275,480 Steven Elms 9,347,549 225,409 Katharine Knobil 9,314,762 258,196 Juan Vera 9,331,093 241,865 Kathryn Penkus Corzo 9,377,143 195,815 Broker Non-Votes: 2,804,902.”
GLOBAL PAYMENTS INC shareholders rejected Advisory vote on shareholder proposal regarding shareholder right to act by written consent. at the 2026-04-30 meeting.
“Proposal 4. Advisory vote on shareholder proposal regarding shareholder right to act by written consent. For Against Abstain Broker Non-Votes 58,311,193 167,913,794 593,341 22,191,119”
GLOBAL PAYMENTS INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent public accounting firm for the year ending December 31, 2026. at the 2026-04-30 meeting.
“Proposal 3. Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent public accounting firm for the year ending December 31, 2026. For Against Abstain Broker Non-Votes 235,165,069 13,648,321 196,057 0”
GLOBAL PAYMENTS INC shareholders approved Advisory vote to approve compensation of the named executive officers for the year ended December 31, 2025. at the 2026-04-30 meeting.
“Proposal 2. Advisory vote to approve compensation of the named executive officers for the year ended December 31, 2025. For Against Abstain Broker Non-Votes 146,640,626 79,718,672 459,030 22,191,119”
GLOBAL PAYMENTS INC shareholders approved Election of Directors at the 2026-04-30 meeting.
“Proposal 1. Election of Directors Board of Directors Nominee For Against Abstain Broker Non-Votes M. Troy Woods 223,200,682 3,541,472 76,174 22,191,119”
AMN HEALTHCARE SERVICES INC shareholders rejected The shareholder proposal entitled 'Independent Board Chairman.' at the 2026-05-01 meeting.
“5. The shareholder proposal entitled “Independent Board Chairman.” This proposal was not approved as set forth immediately below: For Against Abstain Broker Non-Votes 7,495,013 22,327,804 16,599 4,410,527”
AMN HEALTHCARE SERVICES INC shareholders approved The approval of Amendment No. 1 to the AMN Healthcare 2025 Equity Plan. at the 2026-05-01 meeting.
“4. The approval of Amendment No. 1 to the AMN Healthcare 2025 Equity Plan. This proposal was approved as set forth immediately below: For Against Abstain Broker Non-Votes 28,909,689 895,750 33,977 4,410,527”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.